Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 07/05/23
End: 03/03/28
Due: 03/03/29
Phase: N/A
Priority: Normal
Start: 05/04/22
End: 05/15/23
Due: 05/15/24
Phase: N/A
Priority: Normal
Start: 05/01/25
End: 12/31/25
Due: 12/31/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Study in Subjects With Mild-to-Moderate Alzheimer's Dementia | NCT05834296 | Alzamend Neuro, Inc. | user2@example.com | None | 2023-07-05 | 2028-03-03 | 2029-03-03 | - | - | 2025-07-14 |
| Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects | NCT05363293 | Alzamend Neuro, Inc. | user2@example.com | None | 2022-05-04 | 2023-05-15 | 2024-05-15 | - | - | 2025-07-14 |
| A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects | NCT06921590 | Alzamend Neuro, Inc. | user2@example.com | None | 2025-05-01 | 2025-12-31 | 2026-12-31 | - | - | 2025-07-14 |